Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) Overview 6 Therapeutics Development 7 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Products under Development by Stage of Development 7 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Products under Development by Therapy Area 8 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Products under Development by Indication 9 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Pipeline Products Glance 10 Early Stage Products 10 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Products under Development by Companies 11 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Therapeutics Assessment 13 Assessment by Monotherapy/Combination Products 13 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 17 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Companies Involved in Therapeutics Development 19 Vida Therapeutics Inc. 19 Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Drug Profiles 20 Drug to Inhibit Granzyme B for Rheumatoid Arthritis - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 V-2248 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 VTI-1000 Series - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 VTI-1001 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 VTI-1002 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 VTI-2000 Series - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 VTI-3000 Series - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 27 Disclaimer 28

List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 13 Number of Products by Stage and Mechanism of Action, H2 2016 14 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Vida Therapeutics Inc., H2 2016 19 List of Figures Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Top 10 Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Assessment by Monotherapy/Combination Products, H2 2016 13 Number of Products by Stage and Mechanism of Actions, H2 2016 14 Number of Products by Routes of Administration, H2 2016 15 Number of Products by Stage and Routes of Administration, H2 2016 15 Number of Products by Molecule Types, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 17

Vida Therapeutics Inc.